MedTrace Logo

COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses

NCT04483908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 477

Last updated 2022-11-22

No results posted yet for this study

Summary

The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.

Conditions

  • COVID-19 Infection

Interventions

DIAGNOSTIC_TEST

blood draw

2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)

DIAGNOSTIC_TEST

fingertip tests for POC assays

performing POC test by taking two blood drops from the fingertip

DIAGNOSTIC_TEST

saliva collection

saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.

DIAGNOSTIC_TEST

collection of swabs

collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)

Sponsors & Collaborators

  • ETH Zurich (Switzerland)

    collaborator OTHER

  • Health Department of the Canton of Basel-Stadt

    collaborator OTHER_GOV

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Miodrag Savic, Dr. med. · Department of Health, Economics and Health Directorate Canton Basel-Land

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2021-05-30
Completion
2021-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483908 on ClinicalTrials.gov